MSLN and neoplasm: Compared with anti-MSLN CAR-T cells, anti-MSLN CAR-T cells expressing RIAD (CAR-RIAD-T cells) showed enhanced TCR signaling, increased cytokine release, and enhanced killing of tumor cells after exposure to PGE2 or adenosine in vitro.